KAT6A::CREBBP t(8;16)
Quantitative RQ-PCR detection of the KAT6A::CREBBP fusion from t(8;16)(p11;p13) translocation in a subset of AML patients.
KMT2A::AFDN t(6;11) (aka KMT2A::MLLT4 or MLL::AF6)
Quantitative RQ-PCR detection of KMT2A::AFDN fusion transcripts from t(6;11) involving the 11q23 KMT2A locus.
KMT2A::AFF1 t(4;11) (aka MLL::AF4)
Quantitative RQ-PCR detection of KMT2A::AFF1 fusion transcripts from t(4;11), associated with poor prognosis in B-ALL.
KMT2A::MLLT10 (MLL::AF10) t(10;11)
Quantitative RQ-PCR detection of KMT2A::MLLT10 fusion transcripts from the t(10;11) translocation.
ABL1 Tyrosine Kinase Domain Mutation Analysis
Sanger sequencing of ABL1 tyrosine kinase domain to detect imatinib resistance mutations in BCR::ABL1-positive CML, ALL, and AML.
BCR::ABL1 Qualitative Breakpoints p190 vs p210
Qualitative RQ-PCR identification of BCR::ABL1 fusion transcript breakpoint type (major p210 vs minor p190) for diagnosis of CML, ALL, and AML.
CBFA2T3::GLIS2
Quantitative RQ-PCR detection and monitoring of the inv(16)(p13.3q24.3) CBFA2T3::GLIS2 fusion in AML with RAM immunophenotype.
CBFB::MYH11 inv(16) or t(16;16)
Quantitative RQ-PCR detection and monitoring of CBFB::MYH11 fusion transcripts (types A, D, E) from inv(16)/t(16;16) in AML.
DEK::NUP214 t(6;9)
Quantitative RQ-PCR detection and monitoring of the t(6;9)(p22;q34) DEK::NUP214 fusion transcript in AML.
ETV6::RUNX1 t(12;21)
Quantitative RQ-PCR detection of the t(12;21) ETV6::RUNX1 (TEL::AML1) fusion, associated with favorable prognosis in ALL.